-
Patients should be counseled to avoid dehydration, since patients receiving carfilzomib therapy may feel vomiting or diarrhea. Advise patients to seek medical assistance in case they have symptoms of dehydration.
-
Patients should be advised that they may have cough/shortness of breath (dyspnea) while carfilzomib injection treatment. Cough or shortness of breath most commonly occurs within a day of dosing. Instruct patients to contact their doctor in case they feel shortness of breath.
-
Patients should be informed to contact their doctor in case they have neurologic symptoms such as confusion, headaches, seizures, or visual loss.
-
Patients are advised to report pregnancy to their doctor immediately in case they or their female partner becomes pregnant while carfilzomib treatment or within 6 months after the final carfilzomib dose.
-
Patients are advised to avoid breastfeeding while carfilzomib treatment and for 2 weeks after the last dose.
-
Patients are advised to discuss with their healthcare professionals about any medicine they are currently on prior to initiating carfilzomib treatment, or prior to initiating any new drugs during carfilzomib treatment.